Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial
Importance The role of cytomegalovirus (CMV) reactivation in mediating adverse clinical
outcomes in nonimmunosuppressed adults with critical illness is unknown. Objective To
determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL-6) levels in CMV-
seropositive adults who are critically ill. Design, Setting, and Participants Double-blind,
placebo-controlled, randomized clinical trial (conducted March 10, 2011-April 29, 2016) with
a follow-up of 180 days (November 10, 2016) that included 160 CMV-seropositive adults …
outcomes in nonimmunosuppressed adults with critical illness is unknown. Objective To
determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL-6) levels in CMV-
seropositive adults who are critically ill. Design, Setting, and Participants Double-blind,
placebo-controlled, randomized clinical trial (conducted March 10, 2011-April 29, 2016) with
a follow-up of 180 days (November 10, 2016) that included 160 CMV-seropositive adults …